CSL (ASX:CSL) has reached new agreements with the Trump administration covering U.S. drug pricing and domestic manufacturing, adding another important development to the healthcare giant’s recent recovery story. CSL shares finished Tuesday modestly higher, but the bigger move has already happened. The stock has climbed from A$123.06 on July 31 to around A$172 on September 1, a gain of roughly 40% in just over a month.
What Is CSL’s Deal With the Trump Administration?
CSL has entered into two agreements with the U.S. government.
Under an agreement with the U.S. Department of Health and Human Services, CSL will provide Medicaid with access to its current medicines at prices comparable with those available in other developed countries.
The company has also agreed to apply similar pricing to newly launched therapies for all U.S. payers. The arrangement forms part of President Donald Trump’s “most-favored-nation” drug-pricing push, which aims to bring U.S. medicine prices closer to those paid in other developed markets.
CSL was one of nine pharmaceutical companies included in the latest round of agreements. The White House said the deals bring the total number of manufacturers with MFN agreements to 26, representing about 89% of the branded U.S. drug market.
Why Does the Deal Matter for CSL Investors?
One of the most important details for shareholders is the expected financial impact.
CSL said the agreements provide greater certainty around its exposure to U.S. drug-pricing policy and certain Section 232 pharmaceutical tariffs. Crucially, the company does not expect the agreements to have a material impact on its FY27 financial results.
That matters because U.S. drug-pricing reform and possible pharmaceutical tariffs have created uncertainty for global healthcare companies.
The agreement does involve lower pricing in some areas, but CSL now has greater clarity over the rules affecting one of its most important markets.
CSL Is Also Expanding U.S. Manufacturing
The second agreement focuses on manufacturing.
CSL entered into an Onshoring Agreement with the U.S. Department of Commerce reflecting the previously announced $1.5 billion expansion of its manufacturing operations in Kankakee, Illinois.
The project will increase CSL’s capacity to produce immunoglobulins and albumin, therapies used by people living with rare diseases and serious medical conditions.
CSL expects the expansion to create at least 300 pharmaceutical manufacturing jobs and approximately 800 construction and related jobs. The company currently employs about 19,000 people across 44 U.S. states and says it has invested more than $3.1 billion in its U.S. operations since 2018.
Why Have CSL Shares Rallied About 40%?
The Trump agreement comes during a dramatic recovery for CSL shares.
The stock closed at A$123.06 on July 31 before beginning a strong rebound. A major part of that recovery came after CSL released its FY26 results on August 18, when the shares jumped more than 17% in a single session.
CSL reported FY26 underlying NPATA attributable to shareholders of US$3.1 billion. Its statutory result was a US$2.58 billion loss, largely reflecting substantial restructuring and impairment expenses.
More importantly for investors, management expects FY27 revenue to be broadly in line with FY26 and underlying NPAT to grow by approximately 5% at constant currency. CSL Behring is expected to return to mid-single-digit revenue growth, while CSL Seqirus is targeting low-single-digit growth.
That outlook helped restore confidence after a difficult period for the company.
What Should CSL Investors Watch Next?
The Trump deal reduces some policy uncertainty, but CSL still has challenges ahead.
The company needs to deliver its FY27 earnings recovery, maintain momentum in its core plasma business and manage pressure at CSL Vifor, where management expects revenue to decline by around 25% because of generic competition and other product-related headwinds.
Investors will also be watching whether the new U.S. pricing framework creates any larger financial impact beyond FY27.
Conclusion
CSL’s agreements with the Trump administration add another important catalyst to the company’s recovery story.
The agreements expand access to lower drug prices through Medicaid, apply comparable pricing to newly launched therapies for U.S. payers and support CSL’s $1.5 billion manufacturing expansion in Illinois. At the same time, CSL says they provide greater certainty around U.S. pricing and tariff risks without materially affecting FY27 results.
After a roughly 40% share-price rebound since the end of July, the next question for investors is whether CSL can turn improved sentiment and greater policy certainty into sustained earnings growth.
I can also track any major CSL broker upgrades or follow-up details from the U.S. pricing agreements.
